conducted a study in which they observed a specific elevation in serum levels of tissue factor pathway inhibitor 2 (TFPI2) in patients diagnosed with ovarian clear cell carcinoma within the subset of individuals with epithelial ovarian cancer (117). This evidence concerns the gene TFPI2 and ovarian carcinoma.